Literature DB >> 19319544

Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.

Robert D Bell1, Berislav V Zlokovic.   

Abstract

Vascular dysfunction has a critical role in Alzheimer's disease (AD). Recent data from brain imaging studies in humans and animal models suggest that cerebrovascular dysfunction may precede cognitive decline and onset of neurodegenerative changes in AD and AD models. Cerebral hypoperfusion and impaired amyloid beta-peptide (Abeta) clearance across the blood-brain barrier (BBB) may contribute to the onset and progression of dementia AD type. Decreased cerebral blood flow (CBF) negatively affects the synthesis of proteins required for memory and learning, and may eventually lead to neuritic injury and neuronal death. Impaired clearance of Abeta from the brain by the cells of the neurovascular unit may lead to its accumulation on blood vessels and in brain parenchyma. The accumulation of Abeta on the cerebral blood vessels, known as cerebral amyloid angiopathy (CAA), is associated with cognitive decline and is one of the hallmarks of AD pathology. CAA can severely disrupt the integrity of the blood vessel wall resulting in micro or macro intracerebral bleedings that exacerbates neurodegenerative process and inflammatory response and may lead to hemorrhagic stroke, respectively. Here, we review the role of the neurovascular unit and molecular mechanisms in vascular cells behind AD and CAA pathogenesis. First, we discuss apparent vascular changes, including the cerebral hypoperfusion and vascular degeneration that contribute to different stages of the disease process in AD individuals. We next discuss the role of the low-density lipoprotein receptor related protein-1 (LRP), a key Abeta clearance receptor at the BBB and along the cerebrovascular system, whose expression is suppressed early in AD. We also discuss how brain-derived apolipoprotein E isoforms may influence Abeta clearance across the BBB. We then review the role of two interacting transcription factors, myocardin and serum response factor, in cerebral vascular cells in controlling CBF responses and LRP-mediated Abeta clearance. Finally, we discuss the role of microglia and perivascular macrophages in Abeta clearance from the brain. The data reviewed here support an essential role of neurovascular and BBB mechanisms in contributing to both, onset and progression of AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19319544      PMCID: PMC2853006          DOI: 10.1007/s00401-009-0522-3

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  102 in total

1.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.

Authors:  C Nilsberth; A Westlind-Danielsson; C B Eckman; M M Condron; K Axelman; C Forsell; C Stenh; J Luthman; D B Teplow; S G Younkin; J Näslund; L Lannfelt
Journal:  Nat Neurosci       Date:  2001-09       Impact factor: 24.884

Review 2.  Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier.

Authors:  B V Zlokovic
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

3.  Differential degeneration of the cerebral microvasculature in Alzheimer's disease.

Authors:  R N Kalaria; P Hedera
Journal:  Neuroreport       Date:  1995-02-15       Impact factor: 1.837

4.  Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood.

Authors:  O R Monro; J B Mackic; S Yamada; M B Segal; J Ghiso; C Maurer; M Calero; B Frangione; B V Zlokovic
Journal:  Neurobiol Aging       Date:  2002 May-Jun       Impact factor: 4.673

5.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study.

Authors:  A Hofman; A Ott; M M Breteler; M L Bots; A J Slooter; F van Harskamp; C N van Duijn; C Van Broeckhoven; D E Grobbee
Journal:  Lancet       Date:  1997-01-18       Impact factor: 79.321

Review 6.  Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke.

Authors:  John H Griffin; Berislav Zlokovic; José A Fernández
Journal:  Semin Hematol       Date:  2002-07       Impact factor: 3.851

Review 7.  The cerebromicrovasculature: a key player in the pathogenesis of Alzheimer's disease.

Authors:  P Grammas; M Yamada; B Zlokovic
Journal:  J Alzheimers Dis       Date:  2002-06       Impact factor: 4.472

8.  Increased collagen content of cerebral microvessels in Alzheimer's disease.

Authors:  R N Kalaria; A B Pax
Journal:  Brain Res       Date:  1995-12-24       Impact factor: 3.252

9.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease.

Authors:  E H Corder; A M Saunders; N J Risch; W J Strittmatter; D E Schmechel; P C Gaskell; J B Rimmler; P A Locke; P M Conneally; K E Schmader
Journal:  Nat Genet       Date:  1994-06       Impact factor: 38.330

Review 10.  Alzheimer disease and cerebrovascular pathology: an update.

Authors:  K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2002-05       Impact factor: 3.575

View more
  336 in total

1.  Oxidative stress impairs learning and memory in apoE knockout mice.

Authors:  Marianne Evola; Allyson Hall; Trevor Wall; Alice Young; Paula Grammas
Journal:  Pharmacol Biochem Behav       Date:  2010-05-08       Impact factor: 3.533

Review 2.  Alzheimer's Disease: The Link Between Amyloid-β and Neurovascular Dysfunction.

Authors:  Ernesto Solis; Kevin N Hascup; Erin R Hascup
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

3.  Coronary risk correlates with cerebral amyloid deposition.

Authors:  Bruce R Reed; Natalie L Marchant; William J Jagust; Charles C DeCarli; Wendy Mack; Helena C Chui
Journal:  Neurobiol Aging       Date:  2011-11-10       Impact factor: 4.673

4.  Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease.

Authors:  Géraldine Poisnel; Anne-Sophie Hérard; Nadine El Tannir El Tayara; Emmanuel Bourrin; Andreas Volk; Frank Kober; Benoit Delatour; Thierry Delzescaux; Thomas Debeir; Thomas Rooney; Jésus Benavides; Philippe Hantraye; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2011-11-12       Impact factor: 4.673

5.  Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease.

Authors:  Daniel Paris; Nowel Ganey; Magdalena Banasiak; Vincent Laporte; Nikunj Patel; Myles Mullan; Susan F Murphy; Gi-Taek Yee; Corbin Bachmeier; Christopher Ganey; David Beaulieu-Abdelahad; Venkatarajan S Mathura; Steven Brem; Michael Mullan
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

Review 6.  Membrane biophysics and mechanics in Alzheimer's disease.

Authors:  Xiaoguang Yang; Sholpan Askarova; James C-M Lee
Journal:  Mol Neurobiol       Date:  2010-05-01       Impact factor: 5.590

Review 7.  Brain endothelial cell death: modes, signaling pathways, and relevance to neural development, homeostasis, and disease.

Authors:  Maria Teresa Rizzo; H Anne Leaver
Journal:  Mol Neurobiol       Date:  2010-04-21       Impact factor: 5.590

8.  Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease.

Authors:  Tommaso Schirinzi; Giulia Di Lazzaro; Giulia Maria Sancesario; Vito Luigi Colona; Eugenia Scaricamazza; Nicola Biagio Mercuri; Alessandro Martorana; Giuseppe Sancesario
Journal:  J Neural Transm (Vienna)       Date:  2017-09-02       Impact factor: 3.575

9.  Protective Effects of PGC-1α on the Blood Brain Barrier After Acute Kidney Injury.

Authors:  Hao Pan; Junhua Li; Qiaodan Zhou; Fengming Zhu; Siyuan He
Journal:  Neurochem Res       Date:  2020-02-14       Impact factor: 3.996

10.  Myocardin Is Involved in Mesothelial-Mesenchymal Transition of Human Pleural Mesothelial Cells.

Authors:  Torry Tucker; Yoshikazu Tsukasaki; Tsuyoshi Sakai; Shinya Mitsuhashi; Satoshi Komatsu; Ann Jeffers; Steven Idell; Mitsuo Ikebe
Journal:  Am J Respir Cell Mol Biol       Date:  2019-07       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.